Aortic arch tortuosity, a novel biomarker for thoracic aortic disease, is increased in adults with bicuspid aortic valve.
Aortic arch tortuosity, a novel biomarker for thoracic aortic disease, is increased in adults with bicuspid aortic valve.
复制标题
DOI:
10.1016/j.ijcard.2018.10.052
复制
发表时间:
2019-06-01
影响因子:
3.5
通讯作者:
Prakash SK
中科院分区:
文献类型:
--
作者:
Alhafez BA;Truong VTT;Ocazionez D;Sohrabi S;Sandhu H;Estrera A;Safi HJ;Evangelista A;Hurtado LD;Guala A;Prakash SK
Arterial tortuosity has emerged as a predictor of adverse outcomes in congenital aortopathies using 3D reconstructed images. We validated a new method to estimate aortic arch tortuosity on 2D CT. We hypothesize that arch tortuosity may identify bicuspid aortic valve (BAV) patients at high risk to develop thoracic aortic aneurysms or aortic dissections (TAD). BAV subjects with chest CT scans were retrospectively identified in our clinical records and matched to tricuspid aortic valve (TAV) controls by age, gender, and presentation with TAD. Subjects with prior ascending aortic intervention were excluded. Measurements included aortic arch tortuosity, length, angle, width and height. Total aortic tortuosity was estimated in subjects with available abdominal images. 120 BAV and 234 TAV subjects were included. Our 2D measurements were highly correlated with 3D midline arch measurements and had high inter- and intra-observer reliability. Compared to TAV, BAV subjects had increased arch tortuosity (median 1.76 [Q1-Q3: 1.62-1.95] vs. 1.63 [1.53-1.78], P < 0.01), length (149 [136-160] vs. 135 [122-152] mm, P < 0.01),height (46 [41-53]vs. 39[34-7]mm, P < 0.01),and vertex acuity (70[61-77]vs.75 [68-81] degree, P < 0.01). In a multivariable analysis, arch tortuosity remained independently associated with BAV after adjusting for aortic diameter and other clinical characteristics. We found that aortic arch tortuosity is significantly increased in BAV and may identify BAV patients who are at increased risk for TAD. Further studies to evaluate the association between tortuosity and clinical outcomes are in progress.
登录
查看更多内容
影响因子:
6
作者:
Della Corte, Alessandro;Body, Simon C.;Booher, Anna M.;Schaefers, Hans-Joachim;Milewski, Rita K.;Michelena, Hector I.;Evangelista, Arturo;Pibarot, Philippe;Mathieu, Patrick;Limongelli, Giuseppe;Shekar, Prem S.;Aranki, Sary F.;Ballotta, Andrea;Di Benedetto, Giuseppe;Sakalihasan, Natzi;Nappi, Gianantonio;Eagle, Kim A.;Bavaria, Joseph E.;Frigiola, Alessandro;Sundt, Thoralf M.
通讯作者:
Sundt, Thoralf M.
影响因子:
37.8
作者:
Roberts, WC;Ko, JM
通讯作者:
Ko, JM
影响因子:
37.8
作者:
Mahadevia R;Barker AJ;Schnell S;Entezari P;Kansal P;Fedak PW;Malaisrie SC;McCarthy P;Collins J;Carr J;Markl M
通讯作者:
Markl M
影响因子:
3.4
作者:
Poultis, Michael R.;Warwick, Richard;Poole, Robert J.
通讯作者:
Poole, Robert J.
影响因子:
14
作者:
Kang, Joon-Won;Song, Hae Geun;Song, Jae-Kwan
通讯作者:
Song, Jae-Kwan